



06-13-05

1/2W

Express Mail No. EV 577 672 939 US

<p><u>INFORMATION</u> <u>DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. §1.97</u></p> <p>Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p>	Attorney Docket	UCAL-131CON3
	First Named Inventor	PRUSINER, STANLEY B.
	Application Number	10/735,140
	Confirmation No.	5681
	Filing Date	December 12, 2003
	Group Art Unit	1616
	Examiner Name	
	Title: "SODIUM DODECYL SULFATE COMPOSITIONS FOR INACTIVATING PRIONS"	

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08. A copy of each listed publication is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
 - ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
 - ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO/SB/08 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner in the file history of the parent application (Serial No. 10/056,222), copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- ☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).
- ☐ There are no listed references which are not in the English language.
- ☐ The relevance of those listed references which are not in the English language is as follows:

- ☐ Attached are copies of search report(s) from corresponding patent application(s), submitted in accordance with MPEP 609 D in support of the attached certification under 37 CFR 1.97(e)(1).
- ☐ Attached are the following non-published pending patent applications which may be deemed relevant.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number UCAL-131CON3.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP


Date: _____

10/Jan/05

By: _____

Karl Bozicevic
Registration No. 28,807

Bozicevic, Field & Francis, LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/735,140
				Filing Date	December 12, 2003
				First Named Inventor	PRUSINER, STANLEY B.
				Art Unit	1616
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	UCAL-131CON3
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		BLOCK, S.S., "Disinfection, Sterilization, and Preservation (Fourth Edition)" 1991, Lea & Febiger, London, GB XP002325193, Chapter 2: Definition of Terms, pages 18-25			
		CASTLE et al., "Effects of Different Methods of Purification on Aggregation of Scrapie Infectivity" <i>J. Gen. Virol</i> 68:225-231 (1987)			
		DATABASE EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL: 1998, DEALLER, SF, "Transmissible Spongiform encephalopathy: Current and future therapeutic strategies" XP002325195, Database Accession no. EMB-1998210862 *abstract* & Reviews in Medical Microbiology 1998, United Kingdom, vol. 9, no. 3, 1998, pages 135-151, ISSN: 0954-139X			
		DATABASE EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 May 1999 (1999-05-01), SEMAN et al., "Prospects for pharmacological treatment of transmissible subacute spongiform encephalopathies" XP002325196, Database accession no. EMB-1999174466 abstract & Revue du Praticien 01 May 1999 France, vol. 49, no. 9, 1 May 1999 (1999-05-01), pages 971-975, ISSN: 0035-2640			
		URMONEIT et al., "Cationic Lipids (Lipofectamine) and Disturbance of Cellular Cholesterol and aSphingomyelin Distribution Modulates Gamma-Secretase Activity Within Amyloid Precursor Protein <i>In Vitro</i> " <i>Prostaglandins & other Lipid Mediators</i> 55:331-343 (1998)			
Examiner signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.